WS
LGND icon

Wedbush Securities’s Ligand Pharmaceuticals LGND Stock Holding History

Wedbush Securities’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Hold
1,083
– – 0.01% 1086
2025
Q4 		$205K Sell
1,083
-50
-4% -$9.61K 0.01% 1102
2025
Q3 		$201K Buy
+1,133
New +$168K 0.01% 1078

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Wedbush Securities's LGND Position: Q1 2026 in Review

Wedbush Securities held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 1,083 shares worth $216K. The position accounts for 0.01% of the portfolio, ranked #1086.

Wedbush Securities first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Wedbush Securities held 1,083 shares of Ligand Pharmaceuticals worth $216K as of Q1 2026.
  • Wedbush Securities left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up 0.01% of Wedbush Securities's portfolio in Q1 2026, its #1086 holding.
  • Wedbush Securities first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.